Urology

Novel bladder Ca agent shows promise in phase II trialAn investigatory bladder cancer agent was associated with a 12-month high-grade recurrence-free survival of 35% for patients with Ta/T1 disease, researchers reported.
Antibiotics may negatively impact immunotherapy outcomesAdministration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.
PD-1 inhibitor benefit possible even after discontinuationPersistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Research success during residency: Seven useful strategiesUrologic oncology fellow, Ariel Schulman, MD, shares some tips to help residents make research a positive experience.
Planning for retirement: How much is enough?When trying to determine how much is enough when saving for retirement, there are many elements that must be considered. Plus, weigh these pros and cons when deciding how long to receive payments from an immediate annuity.
Ureteroscopy: Surgeons show techniques, tips in videosIn these videos, high-volume stone surgeons demonstrate novel approaches to classification, visualization, and treatment of stones.
Genetic predictors could improve PSA accuracyA recent study has found that genetic predictors of normal PSA levels in healthy men could be used to improve the accuracy of PSA-based prostate cancer screening.
Immunotherapy approved for advanced urothelial CaNivolumab (Opdivo) is the second in class of immune checkpoint inhibitors approved for advanced bladder cancer—treatments that are having “tremendous responses across a spectrum of cancers,” says Leonard G. Gomella, MD.
Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
New Products: Two-in-one wire device combines access, safety guidesOther products discussed include an updated prostate tissue ablation device, a contrast agent for voiding ultrasonography, a bladder cancer test and more.